Lenslet spectacles slowed short-sightedness in US kids, in a maker-run trial

Spectacle lenses dotted with hundreds of tiny lenslets slowed the progression of short-sightedness in American children over two years, cutting the worsening of their prescription by 71% compared with ordinary glasses [s1]. The result is genuine and the trial was rigorously designed — but it comes from a study whose lead author is an employee of Essilor International, the company that makes the lenses, and it directly supports the US clearance of that device [s1]. Both facts belong in the same sentence as the headline number.

Myopia, in which the eyeball grows too long and distant objects blur, is becoming more common in the US and much of the world, and childhood is when it advances fastest [s1]. "Highly aspherical lenslet" (HAL) lenses try to slow that growth by scattering a defocused image across the peripheral retina, a signal that appears to tell the eye to stop elongating. The design has performed well in trials in Asian children, but those results do not automatically transfer, and it had not been proven in a US population — the gap this trial was built to fill [s1].

What the trial did

This was a double-masked randomised trial at nine US sites, enrolling children aged 6 to 12 with mild to moderate myopia (a spherical equivalent refraction of −0.75 to −4.50 dioptres) [s1]. "Double- masked" means neither the families nor the examiners knew who wore which lens, which is the strongest guard against the placebo-like effects that creep into device studies. Children were randomly assigned in equal numbers to HAL lenses or conventional single-vision lenses (SVL) and followed for 24 months [s1].

The trial had two co-primary outcomes, both measured over 24 months: the change in cycloplegic spherical equivalent refraction — the prescription measured with the eye's focusing muscles temporarily relaxed, so the number cannot be gamed — and the change in axial length, the physical elongation of the eyeball that underlies the disease [s1]. Enrolment ran from December 2021 to July 2022, and the 24-month follow-up finished in October 2024 [s1].

What it found

Of 159 children randomised, 135 (84.9%) completed the 24-month assessment [s1]. On the refraction measure, myopia progressed by an adjusted mean of −0.25 dioptres with HAL lenses versus −0.90 dioptres with ordinary lenses — a difference of 0.64 dioptres (95% confidence interval 0.50 to 0.79; P<0.001), which the authors describe as a 71% relative reduction [s1]. On axial length, the eye grew by 0.21 mm with HAL versus 0.45 mm with single-vision lenses, a difference of 0.24 mm (95% CI −0.29 to −0.19; P<0.001), or a 53% relative reduction [s1].

Vision through the lenslet lenses was as sharp as through ordinary ones (mean difference −0.01 logMAR; P=0.23), addressing a common worry that the peripheral blur might degrade everyday sight [s1]. Ocular adverse events occurred in 11.7% of the HAL group and 14.6% of the single-vision group, none serious or lens-related [s1]. These findings, the authors note, underlie the US Food and Drug Administration's authorisation of the device [s1].

How to read it

The effect is real and the trial's methods are strong — randomisation, masking, cycloplegic measurement, and an objective axial-length endpoint are exactly what this field should demand [s1]. The two things to keep in view are the funding and the framing. The lead author is affiliated with Essilor International, which manufactures the lenses; a company-run trial of its own product is not disqualifying, but it warrants the extra scepticism that any commercially motivated study earns, and independent replication would strengthen the case [s1].

On framing, the eye-catching "71%" is a relative reduction, and relative figures always look larger than the absolute change beneath them. In plain terms, over two years a child's prescription worsened by about two-thirds of a dioptre less on the HAL lenses, and the eye grew about a quarter of a millimetre less [s1]. Whether those differences persist, and whether they translate into meaningfully better vision or lower risk of the sight-threatening complications of high myopia in adulthood, this two-year trial cannot say. Related coverage has examined what the evidence shows for myopia-control interventions generally, the role of outdoor time in preventing myopia in children, and whether blue-light glasses do anything.

What to watch

The open questions are durability and independence: whether the slowing holds beyond two years or fades once the lenses come off, and whether investigators without a commercial stake reproduce the size of the effect in US children. Longer follow-up and a hard outcome — vision or complication rates in adulthood, not just millimetres of eye growth — would turn a promising surrogate into proof.

This article describes research and is not medical advice. Decisions about myopia treatment are for eye-care professionals.

Sources

• Spectacle Lenses With Highly Aspherical Lenslets for Myopia Control — JAMA Ophthalmology, 20 August 2026